Infants Receiving Very Early Antiretroviral Therapy Have High CD4 Counts in the First Year of Life

Bryan S Nelson,Camlin Tierney,Deborah Persaud,Jennifer Jao,Mark F Cotton,Yvonne Bryson,Anne Coletti,Theodore D Ruel,Stephen A Spector,Christina Reding,Kira Bacon,Diane Costello,Charlotte Perlowski,Maria Leticia Santos Cruz,Josphat Kosgei,Sai Majji,Dwight E Yin,Patrick Jean-Philippe,Ellen G Chadwick,IMPAACT P1115 Team
DOI: https://doi.org/10.1093/cid/ciac695
2023-02-08
Abstract:We followed 54 infants with in utero HIV after initiating very early antiretroviral treatment. At weeks 24 and 48, ≥80% had CD4 ≥1500 cells/mm3 and CD4% ≥25%. Routine Pneumocystis jirovecii pneumonia prophylaxis in the first year of life may not be necessary for all very early treated infants. Clinical trials registration: NCT02140255.
What problem does this paper attempt to address?